Laurus Labs

The US economy also witnessed substantial issues in its pharma market. In addition to these, manufacturing & exporting countries around the world saw heightened raw material price inflation followed by supply chain disruption. All these…

Drugmaker on Thursday reported a 44% year-on-year (YoY) drop in net profit at Rs 154 crore in Q3FY22 due to lower sales from sales of antiretroviral (ARV) active pharmaceutical ingredients (APIs) and formulations. The company had reported…

NEW DELHI: Foreign brokerage Jefferies has initiated coverage on Gland Pharma and with buy ratings. It has a target of Rs 4,566 on Gland Pharma, valuing the stock at 36.5 times FY24 EPS, in line with its historical one-year forward of 37…